このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Krystal Biotech バランスシートの健全性
財務の健全性 基準チェック /66
Krystal Biotechの総株主資本は$799.2M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$853.3Mと$54.1Mです。
主要情報
0%
負債資本比率
US$0
負債
| インタレスト・カバレッジ・レシオ | n/a |
| 現金 | US$538.26m |
| エクイティ | US$799.24m |
| 負債合計 | US$54.05m |
| 総資産 | US$853.30m |
財務の健全性に関する最新情報
We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02
Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Recent updates
Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
May 13Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
Nov 30Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Sep 27Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Sep 25Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth
Jun 17Krystal Biotech EPS misses by $0.16
May 10Krystal Biotech provides update on pivotal GEM-3 study of B-VEC for DEB
Apr 26Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Mar 02Krystal Biotech secures $125 capital via equity raise
Feb 03財務状況分析
短期負債: KRYSの 短期資産 ( $602.2M ) が 短期負債 ( $47.6M ) を超えています。
長期負債: KRYSの短期資産 ( $602.2M ) が 長期負債 ( $6.5M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: KRYSは負債がありません。
負債の削減: KRYS 5 年前には負債がありませんでした。
債務返済能力: KRYSには負債がないため、営業キャッシュフロー でカバーする必要はありません。
インタレストカバレッジ: KRYSには負債がないため、利息支払い の負担は問題になりません。